The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Smirnova M.D.

National Medical Research Center of Cardiology

Svirida O.N.

Chazov National Medical Research Center of Cardiology

Blankova Z.N.

Chazov National Medical Research Center of Cardiology

Ageev F.T.

Chazov National Medical Research Center of Cardiology

Atherosclerosis and depression. Obvious and non-obvious relationships. Part I

Authors:

Smirnova M.D., Svirida O.N., Blankova Z.N., Ageev F.T.

More about the authors

Journal: Russian Cardiology Bulletin. 2021;16(4): 26‑34

DOI: 10.17116/Cardiobulletin20211604126

Views: 3228

Downloaded: 86

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Smirnova MD, Svirida ON, Blankova ZN, Ageev FT. Atherosclerosis and depression. Obvious and non-obvious relationships. Part I. Russian Cardiology Bulletin. 2021;16(4):26‑34. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20211604126

 
МСФ на ЯМ
Close metadata
Recommended articles:
Diagnostic and prognostic aspe­cts of omentin in cardiovascular diseases. Russian Cardiology Bulletin. 2024;(1):16-22
Lipo­protein(a) and triglyceride-rich lipo­proteins — asso­ciation with recu­rrent nonfatal myocardial infa­rction in patients with early mani­festation of coro­nary artery disease. Russian Cardiology Bulletin. 2024;(1):29-37
The asso­ciation of poly­morphisms of the sero­tonin transporter gene SLC6A4 with depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):135-139
The effect of inso­mnia on mild cognitive impairment in patients with vascular risks: resu­lts of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Vali­dation of screening method based on EEG analysis for the risk asse­ssment of psychiatric and beha­vioral diso­rders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Gender differences in mental and beha­vioural diso­rders as an impo­rtant stage of cardiovascular diseases prevention in young people. Russian Journal of Preventive Medi­cine. 2024;(3):66-71
Possibilities of cardiometabolic diseases prevention in women with pregnancy adve­rse outcomes in medi­cal history. Russian Journal of Preventive Medi­cine. 2024;(3):98-103
Colo­rectal cancer and gut microbiota. P.A. Herzen Journal of Onco­logy. 2024;(2):60-66

This review is devoted to searching for new cardiovascular risk factors in addition to classical ones. Numerous epidemiological and clinical studies confirmed a close relationship between de-pressive disorders and cardiovascular diseases (CVD). Chronic systemic inflammation is consid-ered as a common link in pathogenesis of CVD and depression that is one of the explanations for common combination of these diseases. Depressive disorders and chronic stress can be predictors of systemic inflammation. Hyperactivation of the renin-angiotensin-aldosterone system is consid-ered as an important determinant of systemic inflammation, depressive disorders and abnormal reactions to stress. These findings were confirmed in various experimental studies. Partial over-lapping of atherosclerosis and mental disorder pathways can underlie new therapeutic strategies for the treatment of these diseases.

Keywords:

depression
anxiety
atherosclerosis
inflammation
risk factor
cardiovascular diseases

Authors:

Smirnova M.D.

National Medical Research Center of Cardiology

Svirida O.N.

Chazov National Medical Research Center of Cardiology

Blankova Z.N.

Chazov National Medical Research Center of Cardiology

Ageev F.T.

Chazov National Medical Research Center of Cardiology

Received:

20.09.2021

Accepted:

26.10.2021

List of references:

  1. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. Journal of Psychosomatic Research. 2002;53(4):897-902.  https://doi.org/10.1016/S0022-3999(02)00311-2
  2. Penninx BWJH, Beekman ATF, Honig A, Deeg DJH, Schoevers RA, van Eijk JTM, van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Archives of General Psychiatry. 2001;58(3):221-227.  https://doi.org/10.1001/archpsyc.58.3.221
  3. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993;4(4):285-294.  https://doi.org/10.1097/00001648-199307000-00003
  4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.  https://doi.org/10.1016/S0140-6736(04)17018-9
  5. Pogosova GV. Depression — a risk factor for coronary heart disease and predictor of coronary death: 10 years of scientific research. Kardiologiya. 2012;52(12):4-11. (In Russ.).
  6. Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the precursors study. Archives of Internal Medicine. 1998;158(13):1422-1426. https://doi.org/10.1001/archinte.158.13.1422
  7. Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Vanhala M. Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. The World Journal of Biological Psychiatry. 2010;11(6):834-839.  https://doi.org/10.3109/15622975.2010.486842
  8. Ladwig KH, Baumert J, Marten-Mittag B, Lukaschek K, Johar H, Fang X, Ronel J, Meisinger C, Peters A; KORA Investigators. Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men. Atherosclerosis. 2017;257:224-231.  https://doi.org/10.1016/j.atherosclerosis.2016.12.003
  9. Scherrer JF, Chrusciel T, Zeringue A, Garfield LD, Hauptman PJ, Lustman PJ, Freedland KE, Carney RM, Bucholz KK, Owen R, True WR. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. American Heart Journal. 2010;159(5):772-779.  https://doi.org/10.1016/j.ahj.2010.02.033
  10. Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S, Shaffer JA, Bolton T, Spackman S, Wassertheil-Smoller S, Kee F, Amouyel P, Shea SJ, Kuller LH, Kauhanen J, van Zutphen EM, Blazer DG, Krumholz H, Nietert PJ, Kromhout D, Laughlin G, Berkman L, Wallace RB, Simons LA, Dennison EM, Barr ELM, Meyer HE, Wood AM, Danesh J, Di Angelantonio E, Davidson KW; Emerging Risk Factors Collaboration. Association between Depressive Symptoms and Incident Cardiovascular Diseases. JAMA. 2020;324(23):2396-2405. https://doi.org/10.1001/jama.2020.23068
  11. Smirnova MD, Fofanova TV, Svirida ON, Blankova ZN, Ageev FT. Psychological status of patients and development of cardiovascular complications in patients with arterial hypertension with low and moderate risk by data of ten-year observation. Kardiologicheskii vestnik. 2020;15(2):57-62. (In Russ.). https://doi.org/10.36396/MS.2020.10.34/008
  12. Janszky I, Ahnve S, Lundberg I, Hemmingsson T. Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. Journal of the American College of Cardiology. 2010;56(1):31-37.  https://doi.org/10.1016/j.jacc.2010.03.033
  13. Meyer T, Buss U, Herrmann-Lingen C. Role of cardiac disease severity in the predictive value of anxiety for all-cause mortality. Psychosomatic Medicine. 2010;72(1):9-15.  https://doi.org/10.1097/PSY.0b013e3181c64fc0
  14. Ageev FT, Fofanova TV, Deev AD. The Use of Felodipine in Ambulatory Practice: Assessment of Clinical Efficacy and Compliance in Patients with Arterial Hypertension. Kardiologiia. 2009:49(1):30-33. (In Russ.).
  15. Tillmann T, Läll K, Dukes O, Veronesi G, Pikhart H, Peasey A, Kubinova R, Kozela M, Pajak A, Nikitin Y, Malyutina S, Metspalu A, Esko T, Fischer K, Kivimäki M, Bobak M. Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study. European Heart Journal. 2020;41(35):3325-3333. https://doi.org/10.1093/eurheartj/ehaa571
  16. Denollet J, Schiffer AA, Spek V. A general propensity to psychological distress affects cardiovascular outcomes: Evidence from research on the Type-D (distressed) personality profile. Circulation: Cardiovascular Quality and Outcomes. 2010;3(5):546-557.  https://doi.org/10.1161/CIRCOUTCOMES.109.934406
  17. Saad M, Ray LB, Bujaki B, Parvaresh A, Palamarchuk I, De Koninck J, Douglass A, Lee EK, Soucy LJ, Fogel S, Morin CM, Bastien C, Merali Z, Robillard R. Using heart rate profiles during sleep as a biomarker of depression. BMC Psychiatry. 2019;19(1):168.  https://doi.org/10.1186/s12888-019-2152-1
  18. Davenport L. ECG Promising for Predicting Major Depression, Treatment Response. Medscape-Sep 17, 2020. Accessed November 22, 2021. https://www.medscape.com/viewarticle/937637
  19. Grippo AJ, Beltz TG, Weiss RM, Johnson AK. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biological Psychiatry. 2006;59(4):309-316.  https://doi.org/10.1016/j.biopsych.2005.07.010
  20. Shalnova SA, Deev AD, Belova OA, Grinshtein YI, Duplyakov DV, Efanov AY, Indukaeva EV, Kulakova NV, Libis RA, Nedogoda SV, Rotar OP, Tolparov GV, Trubacheva IA, Chernykh TM, Shabunova AA, Boytsov SA. on behalf of the participants of the ESSE-RF study. Heart Rate and its Association with the Main Risk Factors in the Population of Men and Women of Working Age. Racional’naya farmakoterapiya v kardiologii. 2017;13(6):819-826. (In Russ). https://doi.org/10.20996/1819-6446-2017-13-6-819-826
  21. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. The American Journal of Medicine. 1993;95(1):23-28.  https://doi.org/10.1016/0002-9343(93)90228-h
  22. Freedland KE, Rich MW, Skala JA, Carney RM, Dávila-Román VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosomatic Medicine. 2003;65(1):119-128.  https://doi.org/10.1097/01.psy.0000038938.67401.85
  23. Virchow R. Der atheromatoseprozess der arterien. Wiener Medizinische Wochenschrift. 1856;6:812-827. 
  24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801-809.  https://doi.org/10.1038/362801a0
  25. Buckley ML, Ramji DP. The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. Biochimica et Biophysica Acta. 2015;1852(7):1498-1510. https://doi.org/10.1016/j.bbadis.2015.04.011
  26. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clinical Science. 2018;132(12):1243-1252. https://doi.org/10.1042/cs20180306
  27. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Journal of Lipid Research. 1983;24(8):1070-1076.
  28. Li J, Ley K. Lymphocyte migration into atherosclerotic plaque. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35(1):40-49.  https://doi.org/10.1161/atvbaha.114.303227
  29. Szentes V, Gazdag M, Szokodi I, Dézsi CA. The role of CXCR3 and associated chemokines in the development of atherosclerosis and during myocardial infarction. Frontiers in Immunology. 2018;9:1932. https://doi.org/10.3389/fimmu.2018.01932
  30. Altara R, Manca M, Brandão RD, Zeidan A, Booz GW, Zouein FA. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. Clinical Science. 2016;130(7):463-478.  https://doi.org/10.1042/CS20150666
  31. Titov V.N. Pervichnye i vtorichnyj ateroskleroz, ateromatoz i aterotromboz. M.: Triada; 2008. (In Russ.).
  32. Viola J, Soehnlein O. Atherosclerosis — a matter of unresolved inflammation. Seminars in Immunology. 2015;27(3):184-193.  https://doi.org/10.1016/j.smim.2015.03.013
  33. Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis. 2019;288:146-155.  https://doi.org/10.1016/j.atherosclerosis.2019.07.015
  34. Bertrand MJ, Dubé MP, Tardif JC. Pharmacogenomic approaches to lipid-regulating trials. Current Opinion in Lipidology. 2016;27(6):557-562.  https://doi.org/10.1097/MOL.0000000000000351
  35. Smith RS. The macrophage theory of depression. Medical Hypotheses. 1991;35(4):298-306.  https://doi.org/10.1016/0306-9877(91)90272-Z
  36. Shafiee M, Tayefi M, Hassanian SM, Ghaneifar Z, Parizadeh MR, Avan A, Rahmani F, Khorasanchi Z, Azarpajouh MR, Safarian H, Moohebati M, Heidari-Bakavoli A, Esmaeili H, Nematy M, Safarian M, Ebrahimi M, Ferns GA, Mokhber N, Ghayour-Mobarhan M. Depression and anxiety symptoms are associated with white blood cell count and red cell distribution width: A sex-stratified analysis in a population-based study. Psychoneuroendocrinology. 2017;84:101-108.  https://doi.org/10.1016/j.psyneuen.2017.06.021
  37. Euteneuer F, Dannehl K, Del Rey A, Engler H, Schedlowski M, Rief W. Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial. Translational Psychiatry. 2017;7(5):e1132. https://doi.org/10.1038/tp.2017.76/
  38. Zhou L, Ma X, Wang W. Inflammation and Coronary Heart Disease Risk in Patients with Depression in China Mainland: A Cross-Sectional Study. Neuropsychiatric Disease and Treatment. 2020;16:81-86.  https://doi.org/10.2147/NDT.S216389
  39. Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau F, Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biological Psychiatry. 2008;64(6):476-483.  https://doi.org/10.1016/j.biopsych.2008.04.023
  40. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P; COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain, Behavior, and Immunity. 2020;89:594-600.  https://doi.org/10.1016/j.bbi.2020.07.037
  41. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. The International Journal of Neuropsychopharmacology. 2002;5(4):389-399.  https://doi.org/10.1017/S1461145702003152
  42. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. American Journal of Physiology. Heart and Circulatory Physiology. 2001;281(5):2241-2251. https://doi.org/10.1152/ajpheart.2001.281.5.H2241
  43. Murck H, Held K, Ziegenbein M, Künzel H, Koch K, Steiger A. The renin-angiotensin-aldosterone system in patients with depression compared to controls — a sleep endocrine study. BMC Psychiatry. 2003;3:15.  https://doi.org/10.1186/1471-244X-3-15
  44. Gomez-Sanchez EP. Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends in Endocrinology and Metabolism: TEM. 2011;22(5):179-187.  https://doi.org/10.1016/j.tem.2011.02.001
  45. Francis J, Weiss RM, Johnson AK, Felder RB. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003;284(2):328-335.  https://doi.org/10.1152/ajpregu.00376.2002
  46. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine. 1999;341(10):709-717.  https://doi.org/10.1056/NEJM199909023411001
  47. Baliga RR, Ranganna P, Pitt B, Koelling TM. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. Journal of Cardiac Failure. 2006;12(4):250-246.  https://doi.org/10.1016/j.cardfail.2006.01.013
  48. Marvar PJ, Lob H, Vinh A, Zarreen F, Harrison DG. The central nervous system and inflammation in hypertension. Current Opinion in Pharmacology. 2011;11(2):156-161.  https://doi.org/10.1016/j.coph.2010.12.001
  49. Saavedra JM. Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cellular and Molecular Neurobiology. 2012;32(5):667-681.  https://doi.org/10.1007/s10571-011-9754-6
  50. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. Journal of Clinical Investigation. 2010;120(8):2782-2794. https://doi.org/10.1172/JCI41709
  51. O’Callaghan EL, Bassi JK, Porrello ER, Delbridge LM, Thomas WG, Allen AM. Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures. Journal of Neurochemistry. 2011;119(1):18-26.  https://doi.org/10.1111/j.1471-4159.2011.07406.x
  52. Saavedra JM, Benicky J. Brain and peripheral angiotensin II play a major role in stress. Stress. 2007;10(2):185-293.  https://doi.org/10.1080/10253890701350735
  53. Sánchez-Lemus E, Benicky J, Pavel J, Saavedra JM. In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain, Behavior, and Immunity. 2009;23(7):945-957.  https://doi.org/10.1016/j.bbi.2009.04.012
  54. Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36(4):857-870.  https://doi.org/10.1038/npp.2010.225
  55. Rodrigues SF, Granger DN. Cerebral microvascular inflammation in DOCA salt-induced hypertension: role of angiotensin II and mitochondrial superoxide. Journal of Cerebral Blood Flow and Metabolism. 2012;32(2):368-375.  https://doi.org/10.1038/jcbfm.2011.139
  56. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. Journal of Cerebral Blood Flow and Metabolism. 2005;25(7):878-886.  https://doi.org/10.1038/sj.jcbfm.9600082
  57. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. Journal of Hypertension. 2010;28(8):1730-1737. https://doi.org/10.1097/HJH.0b013e32833a551a
  58. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004;35(7):1726-1731. https://doi.org/10.1161/01.STR.0000129788.26346.18
  59. Swiergiel AH, Dunn AJ. Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacology, Biochemistry, and Behavior. 2007;86(4):651-659.  https://doi.org/10.1016/j.pbb.2007.02.010
  60. Nasr SJ, Crayton JW, Agarwal B, Wendt B, Kora R. Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cellular and Molecular Neurobiology. 2011;31(4):615-618.  https://doi.org/10.1007/s10571-011-9656-7

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.